eliquis apixaban eliquis apixaban eliquis apixaban

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, click here.

For Prescribing and Adverse Event reporting information, click here.

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
SmPC = Summary of Product Characteristics

* ELIQUIS (apixaban) is an oral, direct factor Xa inhibitor indicated for prevention of stroke / systemic embolism in adult patients with NVAF, with one or more risk factors (such as prior stroke or transient ischaemic attack, age ≥ 75 years, hypertension, diabetes mellitus, symptomatic heart failure [New York Heart Association Class ≥ II]), treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.1

† Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

Reference:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.